Global Next Generation Sequencing Market: Trends & Opportunities (2013-2018)
The report titled “Global Next Generation Sequencing Market: Trends and Opportunities (2013-2018)” analyzes the potential opportunities and significant trends in the global Next Generation Sequencing market. The report also provides detailed analysis of the global next generation sequencing market, the Sanger Sequencing market and provides specific focus on the clinical diagnostic opportunities of the NGS technology. The report also profiles and analyzes the business strategies of the leading companies operating in the segment.
Company Profiles
Next Generation Sequencing (NGS) technology has emerged as a higher throughput and much cheaper alternative of sequencing DNA than traditional Sanger Sequencing. NGS can be used primarily to identify genes responsible for inherited skin disease, to detect mutations that play a role in diseases such as cancer and to determine RNA expression level. The use of NGS technology in clinical research and genome functions is constantly increasing and there are many clinical diagnostic opportunities for next generation sequencing such as in oncology screening, parental screening, Alzheimer diseases, multiple sclerosis etc.
The growth of the overall NGS market is driven by continuous innovations and developments in the market aimed at higher throughput, increased accuracy, and affordable costs. However factors such as mismatch between discovery and interpretation of samples, clinical translation of genomic discoveries, difficulty in finding samples to sequence and storage of sequence data hinders the growth of the market. In addition, factors such as high reliability on grants and funding from the government are still a challenge. The opportunities for the growth of this market include developments in the pre-sequencing, cloud computing, and NGS bioinformatics solutions. Next generation sequencing technology is set to revolutionize applied markets like diagnostics, drug discovery, biomarker discovery, personalized medicine, agriculture and animals research in the near future.
Company Profiles
- Illumina
- Life Technology
- Roche
- Pacific Bioscience
Next Generation Sequencing (NGS) technology has emerged as a higher throughput and much cheaper alternative of sequencing DNA than traditional Sanger Sequencing. NGS can be used primarily to identify genes responsible for inherited skin disease, to detect mutations that play a role in diseases such as cancer and to determine RNA expression level. The use of NGS technology in clinical research and genome functions is constantly increasing and there are many clinical diagnostic opportunities for next generation sequencing such as in oncology screening, parental screening, Alzheimer diseases, multiple sclerosis etc.
The growth of the overall NGS market is driven by continuous innovations and developments in the market aimed at higher throughput, increased accuracy, and affordable costs. However factors such as mismatch between discovery and interpretation of samples, clinical translation of genomic discoveries, difficulty in finding samples to sequence and storage of sequence data hinders the growth of the market. In addition, factors such as high reliability on grants and funding from the government are still a challenge. The opportunities for the growth of this market include developments in the pre-sequencing, cloud computing, and NGS bioinformatics solutions. Next generation sequencing technology is set to revolutionize applied markets like diagnostics, drug discovery, biomarker discovery, personalized medicine, agriculture and animals research in the near future.
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1 Genomic
2.1.1 Genome Analysis
2.2 Sanger Sequencing
2.2.1 Comparison between Sanger and Next Generation Sequencing
2.3 Next Generation Sequencing Methods
2.4 High Throughput Sequencing Technologies
2.5 Low Throughput Sequencing Technologies
3. GLOBAL MARKET SIZE OF NEXT GENERATION SEQUENCING INDUSTRY: ANALYSIS AND FORECAST
3.1 Global Market Size of Genomic Tool Industry
3.1.1 Market Share of Genomic Tools Industry by Segment
3.2 Global Market Size of Sequencing Industry
3.3 Global Market Size of Sanger Sequencing Industry
3.3.1 Reasons for Declining Sanger Sequencing Capacity Utilization
3.4 Global Market Size of Next Generation Sequencing Industry
3.5 Next Generation Sequencing Technology Users
3.6 Sequencing Cost per Genome
3.7 Most Limiting Aspects of Next Generation Sequencing Technologies to Workflow
3.8 Funding Source of NGS Labs
4. CLINICAL DIAGNOSTIC OPPORTUNITY FOR NEXT GENERATION SEQUENCING
4.1 NGS Based Test with Clinical Application
5. MARKET DYNAMICS
5.1 Growth Drivers
5.1.1 Increasing Population
5.1.2 Global GDP
5.1.3 Increasing Count of Cancer Patients
5.2 Challenges
5.2.1 Discovery and Interpretation
5.2.2 Clinical Translation of Genomic Discoveries
5.2.3 Finding Samples to Sequence
5.2.4 Compute and Storage for Sequence Data
5.3 Market Trends
5.3.1 Cloud Computing
5.3.2 NGS Bioinformatics
5.3.3 Development in Pre-Sequencing
6. COMPETITIVE LANDSCAPE
6.1 Comparison of High Throughput and Low Throughput Platforms by Company
6.2 Uses of Different Next Generation Systems
6.3 Revenue of the Companies in Next Generation Sequencing Market
6.4 Next Generation Sequencing Market Share by Company
6.5 Next Generation Sequencing Market Share in Clinical Research Application by Company
6.6 Share of Company Products Used by NGS Labs
6.7 Revenue Share of Companies’ Instruments and Reagents
6.8 Comparison of Next Generation Technologies
6.9 Next Generation Sequencing Products Release Timeline by Product Family
7. COMPANY PROFILE
7.1 Illumina Inc
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 Life Technology
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Overview
7.3 Roche
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 Pacific Biosciences of California Inc
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
2. INTRODUCTION
2.1 Genomic
2.1.1 Genome Analysis
2.2 Sanger Sequencing
2.2.1 Comparison between Sanger and Next Generation Sequencing
2.3 Next Generation Sequencing Methods
2.4 High Throughput Sequencing Technologies
2.5 Low Throughput Sequencing Technologies
3. GLOBAL MARKET SIZE OF NEXT GENERATION SEQUENCING INDUSTRY: ANALYSIS AND FORECAST
3.1 Global Market Size of Genomic Tool Industry
3.1.1 Market Share of Genomic Tools Industry by Segment
3.2 Global Market Size of Sequencing Industry
3.3 Global Market Size of Sanger Sequencing Industry
3.3.1 Reasons for Declining Sanger Sequencing Capacity Utilization
3.4 Global Market Size of Next Generation Sequencing Industry
3.5 Next Generation Sequencing Technology Users
3.6 Sequencing Cost per Genome
3.7 Most Limiting Aspects of Next Generation Sequencing Technologies to Workflow
3.8 Funding Source of NGS Labs
4. CLINICAL DIAGNOSTIC OPPORTUNITY FOR NEXT GENERATION SEQUENCING
4.1 NGS Based Test with Clinical Application
5. MARKET DYNAMICS
5.1 Growth Drivers
5.1.1 Increasing Population
5.1.2 Global GDP
5.1.3 Increasing Count of Cancer Patients
5.2 Challenges
5.2.1 Discovery and Interpretation
5.2.2 Clinical Translation of Genomic Discoveries
5.2.3 Finding Samples to Sequence
5.2.4 Compute and Storage for Sequence Data
5.3 Market Trends
5.3.1 Cloud Computing
5.3.2 NGS Bioinformatics
5.3.3 Development in Pre-Sequencing
6. COMPETITIVE LANDSCAPE
6.1 Comparison of High Throughput and Low Throughput Platforms by Company
6.2 Uses of Different Next Generation Systems
6.3 Revenue of the Companies in Next Generation Sequencing Market
6.4 Next Generation Sequencing Market Share by Company
6.5 Next Generation Sequencing Market Share in Clinical Research Application by Company
6.6 Share of Company Products Used by NGS Labs
6.7 Revenue Share of Companies’ Instruments and Reagents
6.8 Comparison of Next Generation Technologies
6.9 Next Generation Sequencing Products Release Timeline by Product Family
7. COMPANY PROFILE
7.1 Illumina Inc
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 Life Technology
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Overview
7.3 Roche
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 Pacific Biosciences of California Inc
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
LIST OF FIGURES
Figure 1: Global Genomic Market Size: 2007 to 2012 (US$ Billion)
Figure 2: Global Genomic Market Size Forecast: 2013 to 2018 (US$ Billions)
Figure 3: Market Share of Genomic Tools Industry by Segment (2012)
Figure 4: Global Sequencing Market Size: 2007 to 2012 (US$ Million)
Figure 5: Global Sequencing Market Size Forecast: 2013 to 2018 (US$ Million)
Figure 6: Global Sanger Sequencing Market Size: 2007 to 2012 (US$ Million)
Figure 7: Global Sanger Sequencing Market Size Forecast: 2013 to 2018 (US$ Million)
Figure 8: Reasons for Declining Sanger Sequencing Capacity Utilization
Figure 9: Global Next Generation Sequencing Market Size: 2007 to 2012 (US$ Million)
Figure 10: Global Next Generation Sequencing Market Size Forecast: 2013 to 2018 (US$ million)
Figure 11: Next Generation Sequencing Technology Users (2013)
Figure 12: Forecasted Next Generation Technology Users
Figure 13: Sequencing Cost per Genome: 2007 to 2012 (US$ Thousand)
Figure 14: Sequencing Cost per Genome Forecasted: 2013 to 2018
Figure 15: Most Limiting Aspects of Next Generation Sequencing Technologies to Workflow
Figure 16: Funding Sources of NGS Labs (2012)
Figure 17: Population Growth by Region: 1990-2010
Figure 18: Global GDP: 2005 to 2012 (US$ Trillion)
Figure 19: Percentage of Deaths from Cancer by Region
Figure 20: Revenue’s of the Companies in NGS Market: 2007 to 2012 (US$ Million)
Figure 21: Next Generation Sequencing Market Share by Company (2012)
Figure 22: Next Generation Sequencing Market Share in Clinical Research Application by Company (2012)
Figure 23: Share of Company Products Used by NGS Labs
Figure 24: Revenue Share of Companies’ Instruments and Reagents: 2009 to 2012
Figure 25: Illumina Inc. Revenue: 2008 to 2012 (US$ Million)
Figure 26: Life Technology Revenue: 2008 to 2012 (US$ Billion)
Figure 27: Roche Revenue: 2008 to 2012 (US$ Billion)
Figure 28: Pacific Biosciences Revenue: 2008 to 2012 (US$ Thousands)
Table 1: Comparison of Next Generation Sequencing (NGS) and Sanger Sequencing
Table 2: Comparison of NGS vs. Traditional Sanger Sequencing on the Basis of Technology
Table 3: Comparison of Different Methods of Next Generation Sequencing
Table 4: Diagnostic Opportunity for Next Generation Sequencing
Table 5: NGS Based Test with Clinical Application
Table 6: Comparison of High Throughput and Low Throughput Cost by Company
Table 7: Comparison of High Throughput and Low Throughput Performance by Company
Table 8: Uses of Different Next Generation Systems
Table 9: Comparison of Next Generation Technologies
Table 10: Next Generation Sequencing Products Release Timeline by Product Family
Figure 1: Global Genomic Market Size: 2007 to 2012 (US$ Billion)
Figure 2: Global Genomic Market Size Forecast: 2013 to 2018 (US$ Billions)
Figure 3: Market Share of Genomic Tools Industry by Segment (2012)
Figure 4: Global Sequencing Market Size: 2007 to 2012 (US$ Million)
Figure 5: Global Sequencing Market Size Forecast: 2013 to 2018 (US$ Million)
Figure 6: Global Sanger Sequencing Market Size: 2007 to 2012 (US$ Million)
Figure 7: Global Sanger Sequencing Market Size Forecast: 2013 to 2018 (US$ Million)
Figure 8: Reasons for Declining Sanger Sequencing Capacity Utilization
Figure 9: Global Next Generation Sequencing Market Size: 2007 to 2012 (US$ Million)
Figure 10: Global Next Generation Sequencing Market Size Forecast: 2013 to 2018 (US$ million)
Figure 11: Next Generation Sequencing Technology Users (2013)
Figure 12: Forecasted Next Generation Technology Users
Figure 13: Sequencing Cost per Genome: 2007 to 2012 (US$ Thousand)
Figure 14: Sequencing Cost per Genome Forecasted: 2013 to 2018
Figure 15: Most Limiting Aspects of Next Generation Sequencing Technologies to Workflow
Figure 16: Funding Sources of NGS Labs (2012)
Figure 17: Population Growth by Region: 1990-2010
Figure 18: Global GDP: 2005 to 2012 (US$ Trillion)
Figure 19: Percentage of Deaths from Cancer by Region
Figure 20: Revenue’s of the Companies in NGS Market: 2007 to 2012 (US$ Million)
Figure 21: Next Generation Sequencing Market Share by Company (2012)
Figure 22: Next Generation Sequencing Market Share in Clinical Research Application by Company (2012)
Figure 23: Share of Company Products Used by NGS Labs
Figure 24: Revenue Share of Companies’ Instruments and Reagents: 2009 to 2012
Figure 25: Illumina Inc. Revenue: 2008 to 2012 (US$ Million)
Figure 26: Life Technology Revenue: 2008 to 2012 (US$ Billion)
Figure 27: Roche Revenue: 2008 to 2012 (US$ Billion)
Figure 28: Pacific Biosciences Revenue: 2008 to 2012 (US$ Thousands)
Table 1: Comparison of Next Generation Sequencing (NGS) and Sanger Sequencing
Table 2: Comparison of NGS vs. Traditional Sanger Sequencing on the Basis of Technology
Table 3: Comparison of Different Methods of Next Generation Sequencing
Table 4: Diagnostic Opportunity for Next Generation Sequencing
Table 5: NGS Based Test with Clinical Application
Table 6: Comparison of High Throughput and Low Throughput Cost by Company
Table 7: Comparison of High Throughput and Low Throughput Performance by Company
Table 8: Uses of Different Next Generation Systems
Table 9: Comparison of Next Generation Technologies
Table 10: Next Generation Sequencing Products Release Timeline by Product Family
